Novel 3-Pyrrolidineindole Derivatives as Serotonergic Psychedelic Agents for Treating Psychosis and Mental Illnesses Such as Depression and Post-Traumatic Stress Disorder.

Provided herein are novel 3-pyrrolidineindole derivatives as serotonergic psychedelic agents, pharmaceutical compositions, use of such compounds in treating psychosis and mental illnesses such as depression and post-traumatic stress disorder, and processes for preparing such compounds.

Novel TYK2 Inhibitors for Treating Autoimmune and Inflammatory Diseases.

Provided herein are novel TYK2 inhibitors, pharmaceutical compositions, use of such compounds in treating autoimmune and inflammatory diseases, and processes for preparing such compounds.

Novel Ergoline Compounds as 5-HT2A Agonists for Treating Mood Disorders Such as Depressive Disorders and Bipolar Disorders.

Provided herein are novel ergoline compounds as 5-HT2A agonists, pharmaceutical compositions, use of such compounds in treating mood disorders such as depressive disorders and bipolar disorders, and processes for preparing such compounds.

Novel Bicyclic Heterocyclic Compounds as CD73 Inhibitors for Treating Cancer.

Provided herein are novel bicyclic heterocyclic compounds as CD73 inhibitors, pharmaceutical compositions, use of such compounds in treating cancer, and processes for preparing such compounds.

Novel Compounds as CDK2 Inhibitors for Treating Cancer.

Provided herein are novel compounds as CDK2 inhibitors, pharmaceutical compositions, use of such compounds in treating cancer, and processes for preparing such compounds.

Pyrrolopyrazine Compounds as ERK5 Inhibitors for Treating Cancer.

Provided herein are novel pyrrolopyrazine compounds as ERK5 inhibitors, pharmaceutical compositions, use of such compounds in treating cancer, and processes for preparing such compounds.

Novel Imidazotriazine Derivatives as IL-17 Modulators for Treating Inflammatory and Autoimmune Disorders.

Provided herein are novel imidazotriazine derivatives as IL-17 modulators, pharmaceutical compositions, use of such compounds in treating inflammatory and autoimmune disorders, and processes for preparing such compounds.

Novel Aryl Hydrocarbon Receptor Agonists for Treating Psoriasis and Atopic Dermatitis.

Provided herein are novel aryl hydrocarbon receptor agonists, pharmaceutical compositions, use of such compounds in treating immune-mediated diseases, in particular psoriasis and atopic dermatitis, and processes for preparing such compounds.

Novel Triazines as NLRP3 Inhibitors for Treating Multiple Diseases.

Provided herein are novel triazines as NLRP3 inhibitors, pharmaceutical compositions, use of such compounds in treating multiple diseases, and processes for preparing such compounds.

Pyridazine Compounds as NLRP3 Inhibitors for Treating Parkinson's Disease or Frontotemporal Dementia.

Provided herein are novel pyridazine compounds as NLRP3 inhibitors, pharmaceutical compositions, use of such compounds in treating Parkinson's disease or frontotemporal dementia, and processes for preparing such compounds.

Novel Pyrrolidinone Urea Compounds as FPR2 Agonists for Treating Atherosclerosis and Heart Failure.

Provided herein are novel pyrrolidinone urea compounds as FPR2 agonists, pharmaceutical compositions, use of such compounds in treating atherosclerosis and heart failure, and processes for preparing such compounds.

Pyrrolidines as Main Protease Inhibitors for Treating Viral Infections, in Particular, Coronavirus Infections.

Provided herein are novel pyrrolidines as main protease inhibitors, pharmaceutical compositions, use of such compounds in treating viral infections, in particular, coronavirus infections, and processes for preparing such compounds.

Novel GIPR Antagonists for Treating Obesity and Type 2 Diabetes Mellitus.

Provided herein are novel GIPR antagonists, pharmaceutical compositions, use of such compounds in treating obesity and type 2 diabetes mellitus and processes for preparing such compounds.

Novel Plasma Kallikrein Inhibitors for Treating Multiple Diseases.

Provided herein are novel plasma kallikrein inhibitors, pharmaceutical compositions, use of such compounds in treating hereditary angioedema, uveitis, posterior uveitis, wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy and retinal vein occlusion and processes for preparing such compounds.

Novel Papain-Like Protease Inhibitors for Treating Viral Infections, in Particular Coronavirus Infections.

Provided herein are novel papain-like protease (PLpro) inhibitors, pharmaceutical compositions, use of such compounds in treating viral infections, in particular coronavirus infections, and processes for preparing such compounds.

Novel Indazole Compounds as PKMYT1 Kinase Inhibitors for Treating Cancer.

Provided herein are novel indazole compounds as PKMYT1 kinase inhibitors, pharmaceutical compositions, use of such compounds in treating cancer, and processes for preparing such compounds.

Pyrazolopyridine and Triazolopyridine Derivatives as DGAT2 Inhibitors for Treating Multiple Diseases.

Provided herein are novel pyrazolopyridine and triazolopyridine derivatives as DGAT2 inhibitors, pharmaceutical compositions, use of such compounds in treating multiple diseases, and processes for preparing such compounds.

Bicyclic Ureas as JAK2 Inhibitors for Treating Hematological Cancer.

Provided herein are novel bicyclic ureas as JAK2 inhibitors, pharmaceutical compositions, use of such compounds in treating hematological cancer, and processes for preparing such compounds.

The reused-disposable scope in flexible ureteroscopy for stones as a cost-conscious approach: Reporting the outcomes of a real-world practice multicenter study of 2183 patients by the team of worldwide endourological researchers group.

Introduction: We aimed to assess complications and stone-free rate of flexible ureteroscopy (FU) reusing disposable scopes (RDS) after repeated sterilization.

Methods: Data from adults from 11 centers were retrospectively reviewed (January 2020-December 2022). Inclusion criteria were proximal ureteral/renal stone(s).

NOVAsort for error-free droplet microfluidics.

High-throughput screening techniques are pivotal to unlocking the mysteries of biology. Yet, the promise of droplet microfluidics in enabling single-cell resolution, ultra-high-throughput screening remains largely unfulfilled. Droplet sorting errors caused by polydisperse droplet sizes that are often inevitable in multi-step assays have severely limited the effectiveness and utility of this technique, especially when screening large libraries.

Novel Azepino[4,5-]indolone as cGAS Inhibitors for Treating Immune-Mediated Diseases.

Provided herein are novel azepino[4,5-]indolone as cGAS inhibitors, pharmaceutical compositions, use of such compounds in treating immune-mediated diseases and processes for preparing such compounds.

Novel Triazolopyridine Derivatives as DGAT2 Inhibitors for Treating Multiple Diseases.

Provided herein are novel triazolopyridine derivatives as DGAT2 inhibitors, pharmaceutical compositions, use of such compounds in treating multiple diseases, and processes for preparing such compounds.